Database includes companies from all three volumes of The Science Coalition's Sparking Economic Growth report.

University Argonne National Laboratory Arizona State University Auburn University Boston University Brown University Columbia University Cornell University Dartmouth College Emory University Florida State University Georgia Institute of Technology Harvard University Indiana University Johns Hopkins University Lawrence Berkeley National Laboratory Marquette University Massachusetts Institute of Technology Michigan Technological University New York University North Carolina State University Northeastern University Northwestern University Ohio State University Pace University Pennsylvania State University Princeton University Rensselaer Polytechnic Institute Rutgers University SLAC Stanford University Stony Brook University Syracuse University Texas A&M University The City University of New York The Rockefeller University University at Buffalo University of Arizona University of California University of California, Berkeley University of California, Davis University of California, Irvine University of California, Los Angeles University of California, Riverside University of California, San Diego University of California, San Francisco University of California, Santa Barbara University of California, Santa Cruz University of Chicago University of Colorado University of Colorado Boulder University of Delaware University of Florida University of Illinois at Chicago University of Illinois at Urbana-Champaign University of Iowa University of Kansas University of Kentucky University of Maryland University of Michigan University of Minnesota University of Mississippi University of Missouri University of Nebraska University of New Hampshire University of New Mexico University of Notre Dame University of Oregon University of Pennsylvania University of Rochester University of South Florida University of Southern California University of Texas at Austin University of Utah University of Virginia University of Washington University of Wisconsin-Madison Virginia Polytechnic Institute and State University Washington State University Wayne State University West Virginia University Yale University

3PrimeDx, Inc. 3primedx-inc 2017 0 UniversityofIllinoisatChicago 2014 IL 1 3PrimeDx is a medical diagnostics company developing a blood test, PulsePredic™, to predict sudden cardiac death (SCD) risk in patients with heart failure. Heart failure occurs in more than 3.5 million Americans each year, but there are no simple, reliable ways of predicting who is at highest risk for SCD and who will benefit from an implanted defibrillator. This blood test will enable the optimization of the intervention by providing a simple, reliable, convenient to administer and cost-effective diagnostic tool. 3PrimeDx is a medical diagnostics company developing a blood test, PulsePredic™, to predict sudden cardiac death (SCD) risk in patients with heart failure. Heart failure occurs in more than 3.5 million Americans each year, but there are no simple, reliable ways of predicting who is at highest risk for SCD and who will benefit from an implanted defibrillator. This blood test will enable the optimization of the intervention by providing a simple, reliable, convenient to administer and cost-effective diagnostic tool. The PulsePredict blood test is based on technology developed by Dr. Samuel C. Dudley while serving as Professor and Chief of Cardiology at the University of Illinois at Chicago. Dr. Dudley discovered that the biomarker changes in the heart leading to sudden cardiac death could also be detected in blood, allowing for a simple diagnostic test. Biomedical Dr. Dudley’s work at UIC was supported by the National Institutes of Health.

Acomni, LLC acomni-llc 2017 0 UniversityofArizona 2014 AZ 1 Acomni was started to put homeowners in control of their heating and cooling budget. The company has developed Ondo™, a Wi-Fi enabled thermostat-monitoring device that gathers data about a home’s heating, ventilation, and air conditioning (HVAC) cycle use. By combing utility rates and weather forecasts with a patent-pending behavioral learning algorithm, Ondo is able to learn a home’s heating and cooling requirements and provide electric utility companies with the ability to visualize energy expenses and estimate future heating and cooling costs. For homeowners, Ondo enables them to heat or cool their home based on how much they want to spend on electricity, not just on how comfortable they want to be. Acomni was started to put homeowners in control of their heating and cooling budget. The company has developed Ondo™, a Wi-Fi enabled thermostat-monitoring device that gathers data about a home’s heating, ventilation, and air conditioning (HVAC) cycle use. By combing utility rates and weather forecasts with a patent-pending behavioral learning algorithm, Ondo is able to learn a home’s heating and cooling requirements and provide electric utility companies with the ability to visualize energy expenses and estimate future heating and cooling costs. For homeowners, Ondo enables them to heat or cool their home based on how much they want to spend on electricity, not just on how comfortable they want to be. Acomni had its genesis in an algorithm created by Dr. Johnathan Sprinkle of the University of Arizona. While working with autonomous sensors to reconstruct river currents he realized that the analysis of river current flows could be applied to HVAC flows throughout a house. Dr. Sprinkle developed the algorithm to do this and then he and his research team applied for the National Science Foundation Innovation Corps competition. Participation in I-Corps allowed them to fully develop their idea and flesh out its commercial value. After being recognized as the best of 27 I-Corps teams, the group founded Acomni. Technology & Web Federal funding from the National Science Foundation helped support the work behind Acomni.

Acoustic Magic, Inc. acoustic-magic-inc 2010 0 BrownUniversity 2000 MA 1 Working in Brown University’s Division of Engineering, Dr. Harvey Silverman and Dr. Michael Brandstein developed a “beam-forming” technology. This technology, now used by Acoustic Magic, has revolutionized microphones.Anyone who has spoken at a conference knows how microphones, even “array” microphones, can limit your movement. The beam forming technology used by Acoustic Magic enables the microphone to “find” a speaker, and filters out noise, echoes and reverberations. The speaker can move about the room freely and be heard with great clarity. In a lecture hall, a professor can speak and be heard and recorded, as can students’ questions or comments, all with one microphone. On a teleconference, several speakers can talk, and the “Voice Tracker” technology enables them all to be heard clearly. The technology is also used for speech dictation. Working in Brown University’s Division of Engineering, Dr. Harvey Silverman and Dr. Michael Brandstein developed a “beam-forming” technology. This technology, now used by Acoustic Magic, has revolutionized microphones.Anyone who has spoken at a conference knows how microphones, even “array” microphones, can limit your movement. The beam forming technology used by Acoustic Magic enables the microphone to “find” a speaker, and filters out noise, echoes and reverberations. The speaker can move about the room freely and be heard with great clarity. In a lecture hall, a professor can speak and be heard and recorded, as can students’ questions or comments, all with one microphone. On a teleconference, several speakers can talk, and the “Voice Tracker” technology enables them all to be heard clearly. The technology is also used for speech dictation. Acoustic Magic is a startup company based upon “beam-forming” technology developed by Dr. Harvey Silverman and Dr. Michael Brandstein of Brown University’s Division of Engineering. Technology & Web The work of Dr. Brandstein and Dr. Silverman was supported by grants from the National Science Foundation. Seed funding for Acoustic Magic was provided by the Slater Center for Interactive Technologies and the Slater Center for Design & Manufacturing Innovation, two of four technology commercialization centers operating under the auspices of Rhode Island’s Samuel Slater Technology Fund.

Aculon, Inc. aculon-inc 2013 0 PrincetonUniversity 2003 CA 1 Aculon, Inc. commercializes unique surface and interfacial coatings leveraging nanotechnology discoveries made at Princeton University. The Company's technology enables coatings to outperform all known alternatives in characteristics such as adhesion, stain resistance, scratch resistance and water and oil repellency. The company's technology is exceptionally versatile and enables several platforms of high-value commercial opportunities. Currently Aculon is focused on two platforms: (1) easy-clean, anti-smudge coatings for eyeglasses and other optical surfaces such as flat panel displays, and stainless steel; and (2) coatings that boost adhesion strength to difficult-to-adhere-to surfaces such as glass, certain metals and plastics. Aculon, Inc. commercializes unique surface and interfacial coatings leveraging nanotechnology discoveries made at Princeton University. The Company's technology enables coatings to outperform all known alternatives in characteristics such as adhesion, stain resistance, scratch resistance and water and oil repellency. The company's technology is exceptionally versatile and enables several platforms of high-value commercial opportunities. Currently Aculon is focused on two platforms: (1) easy-clean, anti-smudge coatings for eyeglasses and other optical surfaces such as flat panel displays, and stainless steel; and (2) coatings that boost adhesion strength to difficult-to-adhere-to surfaces such as glass, certain metals and plastics. The story of Aculon begins with the quest of Dr. Jeffrey Schwartz, Princeton chemistry professor, who sought to understand why orthopedic implants often failed after only 10-15 years of use. He wanted to see if new approaches to modification of the surfaces of implant materials could be achieved to improve their lifetimes. The discoveries of his research team, including Aculon founder Eric Bruner, have led to a new world-wide approach for surface modification of oxide-coated metals and metal oxides. Together, Dr. Schwartz and Bruner invented new surface chemistry to control interfacial properties of indium tin oxide (ITO). This scheme was novel in its ability to attach molecules with tunable properties thereby controlling the properties of the electrode itself. Materials Funding from the National Science Foundation supported the research behind the discoveries and technologies that led to Aculon.

Adarza Biosystems, Inc. adarza-biosystems-inc 2017 0 UniversityofRochester 2008 NY 1 Adarza Biosystems is a leading developer and manufacturer of label-free biosensor assays and instruments servicing life science research, drug development and in vitro diagnostics customers. Adarza’s products and services utilize its proprietary Arrayed Imaging Reflectometry (“AIR™”) detection platform that is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing. The AIR™ technology offers key performance benefits in sensitivity, speed, multiplex arrays, sample size, dynamic range, ease of use and industry leading low cost of use. Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology and infectious diseases research. Adarza Biosystems is a leading developer and manufacturer of label-free biosensor assays and instruments servicing life science research, drug development and in vitro diagnostics customers. Adarza’s products and services utilize its proprietary Arrayed Imaging Reflectometry (“AIR™”) detection platform that is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing. The AIR™ technology offers key performance benefits in sensitivity, speed, multiplex arrays, sample size, dynamic range, ease of use and industry leading low cost of use. Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology and infectious diseases research. Adarza’s highly innovative AIR biosensor was developed at the University of Rochester by Benjamin Miller and Chris Striemer with grant support from the National Institutes of Health. Biomedical The work conducted at the University of Rochester was supported by research funding from the National Institutes of Health.

Adenosine Therapeutics, LLC adenosine-therapeutics-llc 2010 0 UniversityofVirginia 1999 VA 1 Supported by research grants from the National Institutes of Health and the U.S. Department of Agriculture, the University of Virginia has led research into adenosine, a molecule found in all cells. The body uses adenosine to signal inflammation and tissue injury. Understanding this compound has the potential to unleash therapies to treat heart disease, diabetes, arthritis, cancer and atherosclerosis. Joel Linden, University of Virginia professor of cardiovascular medicine and Timothy MacDonald, University of Virginia professor of chemistry recognized the power of this research. They collaborated with business leader Robert Capon to establish a startup company based around University of Virginia patents in this area. Adenosine Therapeutics (ATL), was acquired in 2008 by Clinical Data, a global pharmaceutical company. At the end of 2012, ATL reacquired many of its programs, including Stedivaze. Stedivaze is now more than half way through Phase III trials. Supported by research grants from the National Institutes of Health and the U.S. Department of Agriculture, the University of Virginia has led research into adenosine, a molecule found in all cells. The body uses adenosine to signal inflammation and tissue injury. Understanding this compound has the potential to unleash therapies to treat heart disease, diabetes, arthritis, cancer and atherosclerosis. Joel Linden, University of Virginia professor of cardiovascular medicine and Timothy MacDonald, University of Virginia professor of chemistry recognized the power of this research. They collaborated with business leader Robert Capon to establish a startup company based around University of Virginia patents in this area. Adenosine Therapeutics (ATL), was acquired in 2008 by Clinical Data, a global pharmaceutical company. At the end of 2012, ATL reacquired many of its programs, including Stedivaze. Stedivaze is now more than half way through Phase III trials. Since its founding in 1999 by Joel Linden, University of Virginia professor of cardiovascular medicine and Timothy MacDonald, University of Virginia professor of chemistry, Adenosine Therapeutics has maintained its ties to the University of Virginia and its support of university-based research. In collaboration with many different researchers, the company participated in a large number of Small Business Innovation Research grants, thereby enabling basic and translational research with federal funding. This research has resulted in over 20 patents held by University of Virginia and nearly $3 million in sponsored research by the company. In addition, tens of millions of dollars of University of Virginia basic research grants have been won using Adenosine Therapeutics compounds, and over 100 scientific papers have been published on the pharmacology and physiology of adenosine. The company has given over one million dollars to the University of Virginia Patent Foundation, employed numerous University of Virginia students, and has also participated in business school cases at the Darden Business School. Biomedical Research uncovering adenosine’s role in cell signaling and the development of specialized molecules has been supported by grants from the National Institutes of Health and the U.S. Department of Agriculture.

Advaita Corporation advaita-corporation 2013 0 WayneStateUniversity 2005 MI 1 Advaita's mission is to bridge the gap between the ability to collect biological data and the ability to interpret it through the use of advanced computational methods. The company develops bioinformatics software tools for the research and pharmaceutical industries.Advaita's software platform, Pathway-Guide, is used for the analysis of data from high-throughput microarray and next-generation sequencing experiments. Pathway-Guide is the first tool in a new generation of pathway analysis technologies available on the market that incorporates the topology of the pathway into the analysis. This advanced analysis methodology not only provides more accurate results that correctly identify biologically meaningful pathways in a given disease, but also reduces the number of false-positive results. Advaita's mission is to bridge the gap between the ability to collect biological data and the ability to interpret it through the use of advanced computational methods. The company develops bioinformatics software tools for the research and pharmaceutical industries.Advaita's software platform, Pathway-Guide, is used for the analysis of data from high-throughput microarray and next-generation sequencing experiments. Pathway-Guide is the first tool in a new generation of pathway analysis technologies available on the market that incorporates the topology of the pathway into the analysis. This advanced analysis methodology not only provides more accurate results that correctly identify biologically meaningful pathways in a given disease, but also reduces the number of false-positive results. The genesis of the technology and its initial development took place in the laboratory of Dr. Sorin Draghici, professor of computer science at Wayne State University. Dr. Draghici aimed to create a novel technology for the analysis of biological networks with significant transformative potential for a number of life-science related disciplines that could be used as a predictor of the effectiveness of a drug on a gene. Dr. Draghici and his research team hoped to create a technology that opened a window to view the impact of a drug on an entire organism, essentially creating a roadmap for the potential benefits and pitfalls of any potential drug. Technology & Web The initial research and development was undertaken at Wayne State University with a $1.2 million grant from the National Science Foundation.

Advanced Diamond Technologies (ADT), Inc. advanced-diamond-technologies-adt-inc 2013 0 UniversityofChicagoArgonneNationalLaboratory 2003 IL 1 Advanced Diamond Technologies (ADT) harnesses the superlative properties of nature's perfect material by turning natural gas into diamond in a highly controlled, reproducible process for a variety of industrial, electronic and medical applications. ADT offers several families of high performance UNCD® (ultra-nanocrystalline diamond) products that take advantage of the unsurpassed properties of diamond. ADT is the world leader in developing and applying diamond films for electronic, mechanical, industrial and biomedical applications. Advanced Diamond Technologies (ADT) harnesses the superlative properties of nature's perfect material by turning natural gas into diamond in a highly controlled, reproducible process for a variety of industrial, electronic and medical applications. ADT offers several families of high performance UNCD® (ultra-nanocrystalline diamond) products that take advantage of the unsurpassed properties of diamond. ADT is the world leader in developing and applying diamond films for electronic, mechanical, industrial and biomedical applications. The research of senior scientists Dr. John Carlisle and Dr. Orlando Auciello in the Materials Science Division at Argonne National Laboratory (ANL), led to the discovery of the UNCD® thin film technology that ultimately spawned ADT. Argonne National Laboratory is managed by UChicago Argonne, LLC. Materials Dr. John Carlisle Their work was part of a 10-year Department of Energy-funded basic materials science research program in advanced diamond materials. The program, funded at a level of approximately $800,000 per year, enabled the development of the materials science and resulting inventions that became the basis of UNCD technology. Argonne collaborated with external parties to form a venture company based on UNCD technology and licensed a portfolio of inventions and patents to ADT to form the startup company. Parallel research and product development continued and was funded by various parties.

Advaxis, Inc. advaxis-inc 2010 0 UniversityofPennsylvania 2002 NJ 1 Advaxis, Inc. is a biotechnology company that uses a live genetically modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Advaxis, Inc. is a biotechnology company that uses a live genetically modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based on more than 20 years of innovative work by Yvonne Paterson, PhD, Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously, coordinating innate, humoral (antibody) and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression. Biomedical The basic research at the University of Pennsylvania that led to the development of this technology was supported by research grants from the National Institutes of Health.

Aeglea Biotherapeutics aeglea-biotherapeutics 2017 0 UniversityofTexasatAustin 2013 TX 1 Aeglea is a biotechnology company developing recombinant human enzymes for the treatment of genetic rare diseases and cancers associated with abnormal amino acid metabolism. Aeglea’s product candidates are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in rare diseases or to starve tumors dependent on amino acids. The company is poised to lead the industry in modulating the extremes of amino acid metabolism with its lead product candidate, AEB1102, being investigated for the treatment of patients with Arginase I deficiency and certain types of cancer. Aeglea is a biotechnology company developing recombinant human enzymes for the treatment of genetic rare diseases and cancers associated with abnormal amino acid metabolism. Aeglea’s product candidates are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in rare diseases or to starve tumors dependent on amino acids. The company is poised to lead the industry in modulating the extremes of amino acid metabolism with its lead product candidate, AEB1102, being investigated for the treatment of patients with Arginase I deficiency and certain types of cancer. Blending discovery, technology and drug development is key to success. However, taking protein therapeutics to the clinic requires a very significant investment of time and funding. In 2010, Dr. George Georgiou licensed the intellectual property on two human therapeutic programs from the University of Texas at Austin to a company he founded and self-funded at the seed stage. Several of the technologies licensed resulted from National Institutes of Health funding. In 2013, Dr. David Lowe joined the team as the CEO and co-founded Aeglea Biotherapeutics which became operational in December 2013, with the closing of a $16 million Series A financing. By building a partnership with University of Texas at Austin, Aeglea was able to capitalize on the broadly accepted but underexploited concept of developing engineered human enzymes to target amino acids in the blood. As company co-founder Dr. Lowe explained, “The understanding that human enzymes could be engineered to increase activity while avoiding the possible immune responses seen with microbial proteins was a breakthrough moment that inspired me to found Aeglea. Having a background in biomedical research, I recognized this discovery as an exciting opportunity to address a critical need among patients who have extremely limited treatment options, which is a guiding principle of our company.” Biomedical The work conducted at the University of Texas at Austin was supported by research funding from the National Institutes of Health.

Agensys, Inc. agensys-inc 2010 0 UniversityofCaliforniaLosAngelesUniversityofCalifornia 1996 CA 101 In 1996, Dr. Don Rice and researchers from the Urology Department at the David Geffen School of Medicine at University of California, Los Angeles (UCLA), founded UroGenesys, now called Agensys. The company got its start when the UCLA researchers, funded by the National Institutes of Health, discovered genes associated with certain solid tumor cancers. These discoveries led to the development of antibody treatments for those cancers. Company co-founder Dr. Arie Belldegrun told Medical News Today “As clinicians and scientists, we wanted to build on the discoveries made in our individual labs to help move cancer research forward from the bench to the bedside.” The company started with four patents and a handful of employees and has grown into a robust biotechnology company that conducts antibody R&D for 14 different types of cancer and is capable of bringing a product all the way through early-stage clinical trials. The company has discovered and developed a large portfolio of novel clinically relevant targets for prostate, bladder, pancreatic, and kidney cancers. Agensys was acquired by Astellas Pharma US, the US affiliate of Tokyo-based Astellas Pharma, Inc., in December 2007. When Astellas Pharma acquired Agensys in 2007, a portion of the selling price went to UCLA as part of a groundbreaking licensing agreement in which the university received part equity in the firm as partial consideration. In 1996, Dr. Don Rice and researchers from the Urology Department at the David Geffen School of Medicine at University of California, Los Angeles (UCLA), founded UroGenesys, now called Agensys. The company got its start when the UCLA researchers, funded by the National Institutes of Health, discovered genes associated with certain solid tumor cancers. These discoveries led to the development of antibody treatments for those cancers. Company co-founder Dr. Arie Belldegrun told Medical News Today “As clinicians and scientists, we wanted to build on the discoveries made in our individual labs to help move cancer research forward from the bench to the bedside.” The company started with four patents and a handful of employees and has grown into a robust biotechnology company that conducts antibody R&D for 14 different types of cancer and is capable of bringing a product all the way through early-stage clinical trials. The company has discovered and developed a large portfolio of novel clinically relevant targets for prostate, bladder, pancreatic, and kidney cancers. Agensys was acquired by Astellas Pharma US, the US affiliate of Tokyo-based Astellas Pharma, Inc., in December 2007. When Astellas Pharma acquired Agensys in 2007, a portion of the selling price went to UCLA as part of a groundbreaking licensing agreement in which the university received part equity in the firm as partial consideration. Agensys, Inc. was founded as UroGenesys in 1996 by Dr. Don Rice and researchers from the Urology Department at the David Geffen School of Medicine at UCLA. The early goal was to discover genes and develop drugs to use in the treatment of prostate cancer. Toward that aim, the UCLA Office of Intellectual Property licensed four patents to the fledgling company, which used them to raise $8 million in the first round of venture capital financing. Biomedical The National Institutes of Health funded the UCLA research that led to discoveries patented by Agensys’ founders, such as their proprietary target Prostate Stem Cell Antigen (PSCA).

Agile Sciences, Inc. agile-sciences-inc 2013 0 NorthCarolinaStateUniversity 2007 NC 1 Agile Sciences, Inc. provides commercial solutions to industries plagued by the effects of biofilms. A bacterial biofilm is a community of bacterial cells that are attached to a surface and are protected by an extracellular matrix, making them exceptionally hardy and difficult to deal with. Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics and immune systems than free-floating bacteria. In agriculture, every year billions of dollars of crops are lost due to the formation of biofilms. Industrial needs for effective biofilm dispersion include surface coatings and cleansing products. Agile Sciences technology is based on a family of novel organic compounds that have potent anti-biofilm properties. The molecular architecture of the compounds is highly tunable for addressing specific needs in a diverse array of product markets. Agile Sciences, Inc. provides commercial solutions to industries plagued by the effects of biofilms. A bacterial biofilm is a community of bacterial cells that are attached to a surface and are protected by an extracellular matrix, making them exceptionally hardy and difficult to deal with. Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics and immune systems than free-floating bacteria. In agriculture, every year billions of dollars of crops are lost due to the formation of biofilms. Industrial needs for effective biofilm dispersion include surface coatings and cleansing products. Agile Sciences technology is based on a family of novel organic compounds that have potent anti-biofilm properties. The molecular architecture of the compounds is highly tunable for addressing specific needs in a diverse array of product markets. Agile Sciences was co-founded by North Carolina State University professors Christian Melander and John Cavanagh. Dr. Melander focuses on defining small molecules that inhibit and disperse bacterial biofilms and Dr. Cavanagh is an expert in protein structural biology, particularly in how bacteria are able to protect themselves. It was through a conversation with each other about their work that they each realized they needed the other scientist’s expertise to complement and complete their own work. The ensuing collaboration resulted in the technology behind Agile Sciences. Energy & Chemicals John Cavanagh Melander and Cavanagh's research at NC State received funding from the National Institutes of Health and the National Science Foundation.

Agilis Biotherapeutics agilis-biotherapeutics 2017 0 UniversityofSouthFlorida 2013 MA 1 Agilis Biotherapeutics is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis’ technology enables precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. One of the company’s lead programs is focused on Angelman syndrome (AS), a rare disorder characterized by a severe cognitive disability. It is believed that a loss of UBE3A gene function in the brain causes many of the characteristic features og AS. Agilis Biotherapeutics is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis’ technology enables precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. One of the company’s lead programs is focused on Angelman syndrome (AS), a rare disorder characterized by a severe cognitive disability. It is believed that a loss of UBE3A gene function in the brain causes many of the characteristic features og AS. University of South Florida’s Dr. Edwin Weeber, one of the world’s foremost AS investigators, was the first to demonstrate the use of an effective gene therapy treatment for AS in the gold standard mouse model. Dr. Weeber received a grant from the National Institutes of Health to establish the viability of three distinct therapeutic strategies to ameliorate the severe cognitive impairments exhibited by AS individuals. Agilis exclusively licensed the gene therapy technology developed by Dr. Weeber, providing an excellent platform to develop an effective UBE3A gene therapy for patients with AS. Biomedical The work conducted at the University of South Florida was supported by research funding from the National Institutes of Health.

AGTC agtc 2017 0 UniversityofFlorida 1999 FL 51 AGTC is developing treatments for rare eye diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, the company uses cutting-edge techniques to develop treatments for patients who have diseases caused by broken genes. AGTC uses gene therapy, which replaces those broken genes with normal, functional genes, allowing a patient’s own body to produce proteins to treat the illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. AGTC is developing treatments for rare eye diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, the company uses cutting-edge techniques to develop treatments for patients who have diseases caused by broken genes. AGTC uses gene therapy, which replaces those broken genes with normal, functional genes, allowing a patient’s own body to produce proteins to treat the illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. The innovative delivery method AGTC uses is the non-toxic adeno-associated virus (AAV), a safe virus that delivers healthy copies of the gene, replacing defective copies. Company co-founder Dr. Nicholas Muzyczka, a microbiology professor at the University of Florida, was the first scientist to demonstrate the use of an AAV as a vector for transporting the corrective genes used in gene therapy. His work in the field spanned decades and was supported by the National Eye Institute, part of the National Institutes of Health. During this time, two other labs – those of AGTC co-founders Dr. Barry Byrne and Dr. Jude Samulski – conducted experiments on mice showing that the genetic material was long-lasting and would keep working over time. Knowing that they were onto something significant, the scientists approached large pharmaceutical companies about conducting clinical trials of the gene therapy treatments. Turned down by these companies, Dr. Muzyczka and four fellow scientists from UF and the University of North Carolina struck out on their own, founding Applied Genetic Technologies Corporation, or AGTC, in 1999. Biomedical The work at the University of Florida was supported by research funding from the National Institutes of Health.

Akamai Technologies, Inc. akamai-technologies-inc 2013 0 MassachusettsInstituteofTechnology 1999 MA 1001 Akamai is the leading global service provider for accelerating content and business processes online.Akamai has deployed the most pervasive, highly-distributed cloud optimization platform with over 127,000 servers in 81 countries within over 1,150 networks. It delivers between 15-30 percent of all Web traffic, with daily Web traffic reaching more than 10 Terabits per second. It also delivers over 2 trillion daily Internet interactions and helps securely enable more than $250 billion in annual e-commerce for its online retail customers. Akamai is the leading global service provider for accelerating content and business processes online.Akamai has deployed the most pervasive, highly-distributed cloud optimization platform with over 127,000 servers in 81 countries within over 1,150 networks. It delivers between 15-30 percent of all Web traffic, with daily Web traffic reaching more than 10 Terabits per second. It also delivers over 2 trillion daily Internet interactions and helps securely enable more than $250 billion in annual e-commerce for its online retail customers. In 1996, Dr. Tom Leighton, a renowned expert on parallel algorithms and architecture and head of the Algorithms Group at MIT's Laboratory for Computer Science, recognized that a solution to web congestion could be found in applied mathematics and algorithms. He solicited the help of graduate student Danny Lewin, and several other top researchers, to tackle the problem. With funding support from the Department of Defense, through DARPA and the Army Research Office, they developed a set of breakthrough algorithms for intelligently routing and replicating content over a large network of distributed servers — without relying on centralized servers typically used by Web site owners today. This novel coding, called consistent hashing, would evolve into the core of Akamai’s commercial technology, essentially duplicating a client’s online content — HTML code, media, software downloads, and so on — and redirecting its customers to an Akamai server with the best connection for faster download times and fewer vulnerabilities to network issues.Their research was published in 1997. Jonathan Seelig, then enrolled in the MIT Sloan MBA program, joined the founding team, and they began building the business plan that would lead to Akamai's inception. Akamai obtained an exclusive license to certain intellectual property from MIT, and development efforts began in the fall of 1998. The company launched commercial service in April 1999. Technology & Web The groundbreaking algorithms research that led to the founding of Akamai was funded by the Department of Defense, through DARPA and the Army Research Office

Akrivis Technologies akrivis-technologies 2013 0 NortheasternUniversity 2009 MA 1 Akrivis Technologies seeks to improve patients’ health and reduce healthcare costs by developing safer and more efficacious cancer therapies, and by providing rapid, ultrasensitive and low–cost diagnostics for both research and clinical applications. The company’s core Z–TECT™ technology platform is based on a patented, nanotechnology–derived signal amplification system that provides accurate and reproducible detection of less than a thousand individual molecules. Z–TECT™ also can serve as a novel platform for the targeted delivery of radio– and chemo–therapeutic drugs for cancer treatments. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z–TECT™ could have a major impact on the emerging field of “Theranostics” which combines cancer therapies with in vivo imaging diagnostics. Akrivis Technologies seeks to improve patients’ health and reduce healthcare costs by developing safer and more efficacious cancer therapies, and by providing rapid, ultrasensitive and low–cost diagnostics for both research and clinical applications. The company’s core Z–TECT™ technology platform is based on a patented, nanotechnology–derived signal amplification system that provides accurate and reproducible detection of less than a thousand individual molecules. Z–TECT™ also can serve as a novel platform for the targeted delivery of radio– and chemo–therapeutic drugs for cancer treatments. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z–TECT™ could have a major impact on the emerging field of “Theranostics” which combines cancer therapies with in vivo imaging diagnostics. Akrivis was co–founded in 2009 by Dr. Ban–An Khaw, Behrakis Professor of Pharmaceutical Sciences at Northeastern University, to further develop and commercialize his lifelong work and discoveries on novel ultrasensitive and low–cost immunoassays. The novel delivery mechanism behind Akrivis was originally developed by Dr. Khaw to identify cardiac cell death. Biomedical The foundational work essential to the development of the Akrivis technology was conducted by Khaw at Northeastern University with support from the National Institute of Health.

ALEKS Corporation aleks-corporation 2010 0 UniversityofCaliforniaIrvineUniversityofCalifornia 1996 CA 101 ALEKS Corporation is a leader in the creation of web-based, artificially intelligent educational software. ALEKS assessment and learning technologies were originally developed by a team of cognitive scientists and software engineers at the University of California, Irvine, with major funding from the National Science Foundation. ALEKS is founded on ground-breaking research in mathematical cognitive science and applied mathematics. Through adaptive questioning, ALEKS accurately assesses a student’s knowledge state and then delivers targeted instruction on the exact topics a student is most ready to learn. ALEKS has been used by millions of students in more than 50 academic subjects ranging from basic math to precalculus at thousands of institutions throughout the world. ALEKS Corporation is a leader in the creation of web-based, artificially intelligent educational software. ALEKS assessment and learning technologies were originally developed by a team of cognitive scientists and software engineers at the University of California, Irvine, with major funding from the National Science Foundation. ALEKS is founded on ground-breaking research in mathematical cognitive science and applied mathematics. Through adaptive questioning, ALEKS accurately assesses a student’s knowledge state and then delivers targeted instruction on the exact topics a student is most ready to learn. ALEKS has been used by millions of students in more than 50 academic subjects ranging from basic math to precalculus at thousands of institutions throughout the world. In 1993, Dr. Jean-Claude Falmagne assembled a team of software engineers, mathematicians, and cognitive scientists at University of California, Irvine. Dr. Falmagne’s team created the core of the ALEKS interactive software system for portions of the arithmetic and algebra curricula. In May 1997, ALEKS Corporation and the University of California entered into an exclusive worldwide license. Education & Language Dr. Falmagne’s software was developed with support from grants from the National Science Foundation.

Allegro Diagnostics allegro-diagnostics 2013 0 BostonUniversity 2008 MA 1 Allegro Diagnostics Corp. is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests to support the diagnosis and management of lung cancer. These tests have the potential to enable the early diagnosis, staging and informed treatment of lung cancer and other lung diseases.The company has developed a molecular testing platform that is based on the discovery of a genomic biomarker for lung cancer. This platform has generated multiple product candidates that analyze specific changes in gene expression in epithelial cells of the airway, which are associated with the development in lung cancer in current or former tobacco smokers. Allegro Diagnostics Corp. is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests to support the diagnosis and management of lung cancer. These tests have the potential to enable the early diagnosis, staging and informed treatment of lung cancer and other lung diseases.The company has developed a molecular testing platform that is based on the discovery of a genomic biomarker for lung cancer. This platform has generated multiple product candidates that analyze specific changes in gene expression in epithelial cells of the airway, which are associated with the development in lung cancer in current or former tobacco smokers. Allegro Diagnostics was spun off from research by Dr. Avrum Spira and Dr. Jerry Brody, professors at Boston University’s School of Medicine. Dr. Spira and Dr. Brody wanted to address a major public health issue: lung cancer, the leading cause of cancer death in the United State and the world. Lung cancer’s high mortality rate relates to the physician’s inability to detect it at an early and curable stage. Dr. Spira and Dr. Brody leveraged the concept that molecular alterations in relatively accessible epithelial cells that line the upper airway could serve as biomarkers for the early detection of lung cancer among smokers. They developed a gene-expression signature in these cells that can accurately distinguish smokers with lung cancer from those without the disease and serve as a clinically relevant biomarker. Allegro Diagnostics was spun off from research by Dr. Avrum Spira and Dr. Jerry Brody, professors at Boston University’s School of Medicine. Dr. Spira and Dr. Brody wanted to address a major public health issue: lung cancer, the leading cause of cancer death in the United State and the world. Lung cancer’s high mortality rate relates to the physician’s inability to detect it at an early and curable stage. Dr. Spira and Dr. Brody leveraged the concept that molecular alterations in relatively accessible epithelial cells that line the upper airway could serve as biomarkers for the early detection of lung cancer among smokers. They developed a gene-expression signature in these cells that can accurately distinguish smokers with lung cancer from those without the disease and serve as a clinically relevant biomarker.X Biomedical The initial research and development behind Allegro Diagnostics was conducted at BU with a $300,000 grant from the National Institutes of Health, through the National Cancer Institute. Allegro has raised about $10M from venture capital and $3M from non-dilutive sources.

Allylix, Inc. allylix-inc 2010 0 UniversityofKentucky 2002 CA NA Using proprietary technology developed in 2002 at the University of Kentucky’s College of Agriculture and the Salk Institute for Biological Studies, Allylix has developed a way to produce a group of natural products called “terpenes” at low cost. In nature, plants produce minute quantities of terpenes to serve a number of different functions. Some are flavors and fragrances, others are anti-fungal and anti-viral and still others are insect repellents. Despite their enormous potential commercial value to the flavor and fragrance, insect repellent and pharmaceutical industries, terpenes have been underexploited because of high production costs. Allylix’s proprietary technology platform has changed that. Allylix’s technology could soon make your fruit juice taste more citrusy when the company’s version of nookatone is commercialized. Nookatone, one of three sesquiterpenes that Allylix is working with, is a grapefruit flavor that will be produced using yeast grade fermentation. Allyix recently licensed technology to a leading clean technology company to produce a specific class of terpenes for use in the development of fuels and fuel additives. Allylix was acquired by Evolva in 2014. Using proprietary technology developed in 2002 at the University of Kentucky’s College of Agriculture and the Salk Institute for Biological Studies, Allylix has developed a way to produce a group of natural products called “terpenes” at low cost. In nature, plants produce minute quantities of terpenes to serve a number of different functions. Some are flavors and fragrances, others are anti-fungal and anti-viral and still others are insect repellents. Despite their enormous potential commercial value to the flavor and fragrance, insect repellent and pharmaceutical industries, terpenes have been underexploited because of high production costs. Allylix’s proprietary technology platform has changed that. Allylix’s technology could soon make your fruit juice taste more citrusy when the company’s version of nookatone is commercialized. Nookatone, one of three sesquiterpenes that Allylix is working with, is a grapefruit flavor that will be produced using yeast grade fermentation. Allyix recently licensed technology to a leading clean technology company to produce a specific class of terpenes for use in the development of fuels and fuel additives. Allylix was acquired by Evolva in 2014. Allylix, Inc., a technology leader in the science and low-cost production of terpenes, is using proprietary technology developed in 2002 at the University of Kentucky’s College of Agriculture and the Salk Institute for Biological Studies. Allylix has a research and development center at the University of Kentucky’s Coldstream Research Campus in Lexington. Energy & Chemicals Early work that led to technologies used by Allylix received support from National Science Foundation.

Amati Communications Corporation amati-communications-corporation 2010 0 StanfordUniversity 1992 CA NA In 1992, many people were touting fiber optic cables as the answer to growing consumer demand for bandwidth. Stanford researchers developed technology related to Discrete Multi-Tone (DMT) technology, the technology that came to be used in Asymmetric Digital Subscriber Line (ADSL) which provides broadband internet access to homes and businesses around the world. ADSL was revolutionary because it enabled use of the common telephone line to transmit large amounts of data quickly — at rates 30–100 times faster than the 56K analog modems. In 1992, Stanford’s Office of Technology Licensing issued an exclusive license to four patents to Amati Communications Corporation, which was founded by Stanford Professor John Cioffi. In 1995, Amati merged with ICOT, which was then acquired by Texas Instruments in 1998. In 1992, many people were touting fiber optic cables as the answer to growing consumer demand for bandwidth. Stanford researchers developed technology related to Discrete Multi-Tone (DMT) technology, the technology that came to be used in Asymmetric Digital Subscriber Line (ADSL) which provides broadband internet access to homes and businesses around the world. ADSL was revolutionary because it enabled use of the common telephone line to transmit large amounts of data quickly — at rates 30–100 times faster than the 56K analog modems. In 1992, Stanford’s Office of Technology Licensing issued an exclusive license to four patents to Amati Communications Corporation, which was founded by Stanford Professor John Cioffi. In 1995, Amati merged with ICOT, which was then acquired by Texas Instruments in 1998. Amati Communications Corporation began as a research project by Prof. John Cioffi and graduate students Jacky Chow, Peter Chow, Minnie Ho and Huiling Lou at Stanford University. Technology & Web Dr. Cioffi’s early research was supported in part by the National Science Foundation.

American BioOptics american-biooptics 2013 0 NorthwesternUniversity 2006 IL 1 American BioOptics LLC (ABO) is a medical device company founded to commercialize a novel optical technology platform for cancer screening and detection. This technology shines light inside the colon and analyzes how the reflected light interacts with the lining of the colon. This interaction provides unique insight into abnormalities in healthy appearing tissue that are too small to be seen with an endoscope or microscope. Based on a patented discovery at Northwestern University and NorthShore University HealthSystem, this technology is now harnessed in a commercial‐ready mobile instrumentation system and highly sensitive, easy‐to‐use, minimally invasive test for screening for colorectal cancer (CRC). American BioOptics LLC (ABO) is a medical device company founded to commercialize a novel optical technology platform for cancer screening and detection. This technology shines light inside the colon and analyzes how the reflected light interacts with the lining of the colon. This interaction provides unique insight into abnormalities in healthy appearing tissue that are too small to be seen with an endoscope or microscope. Based on a patented discovery at Northwestern University and NorthShore University HealthSystem, this technology is now harnessed in a commercial‐ready mobile instrumentation system and highly sensitive, easy‐to‐use, minimally invasive test for screening for colorectal cancer (CRC). In 2002, ABO’s founding scientific and clinical team at Northwestern University and the Research Institute of Evanston Northwestern Healthcare (now NorthShore University Health System, an affiliate of the University of Chicago Pritzker School of Medicine) began development of the company’s optical backscattering technologies. Biomedical This early work, supported by the National Institutes of Health, focused on the development of the company’s optical backscattering technology system and optical probes in the Biomedical Engineering Department at Northwestern. The research included significant early investigation at Evanston Northwestern Healthcare of optical biomarkers in animal models and later in human subjects to predict patients likely to be at risk of colon cancer.

Amyris, Inc. amyris-inc 2013 0 UniversityofCaliforniaBerkeleyUniversityofCalifornia 2003 CA 101 Amyris is a renewable products company providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris applies its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Biofene is Amyris’s brand of a long-chain, branched hydrocarbon molecule called farnesene (trans-ß-farnesene). This building block molecule forms the basis for a wide range of products from specialty products such as cosmetics, perfumes, detergents and industrial lubricants, to transportation fuels such as diesel and jet fuel. The company’s first product was artemisinic acid, which is used to make malaria drugs. A variety of new molecules with different applications are under development. Amyris is a renewable products company providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris applies its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Biofene is Amyris’s brand of a long-chain, branched hydrocarbon molecule called farnesene (trans-ß-farnesene). This building block molecule forms the basis for a wide range of products from specialty products such as cosmetics, perfumes, detergents and industrial lubricants, to transportation fuels such as diesel and jet fuel. The company’s first product was artemisinic acid, which is used to make malaria drugs. A variety of new molecules with different applications are under development. Professor Jay D. Keasling of the University of California, Berkeley and his research group, including postdoctoral fellows Jack Newman, Kinkead Reiling and Neil Renninger, developed the company’s foundational method. This platform technology uses synthetic biology to turn microbes such as bacteria and yeast into factories that overproduce compounds based on isoprenes/terpene chemical building blocks. Their research was funded by the National Science Foundation and Department of Defense through the Office of Naval Research. Energy & Chemicals UC Berkeleyfiled patents on the basic method, and through a series of contracts, sub-contracts, and funding from the Bill and Melinda Gates Foundation, ensured that the final artemisinin-based malaria treatments would be available at a low cost to those in 88 economically disadvantaged countries. The “humanitarian use”clauses in the contracts, along with the associated IP management strategies and business models, were recognized through a “Patents for Humanity” award from the U.S. Patent and Trademark Office to UC Berkeleyin 2013.

AnswerDash, Inc. answerdash-inc 2017 0 UniversityofWashington 2013 WA 1 AnswerDash provides contextual, self-service help for websites, improving the online experience that businesses deliver to their customers. AnswerDash provides this help by overlaying onto the periphery of existing web pages a small tab that, when clicked by visitors, expands into a panel containing questions commonly asked about the host web page. By clicking on one of the common questions, a visitor receives the corresponding answer. The panel then shrinks back into a tab, allowing the visitor to continue with their web-based task, having received instant, self-service help with no typing and only a few clicks. AnswerDash provides contextual, self-service help for websites, improving the online experience that businesses deliver to their customers. AnswerDash provides this help by overlaying onto the periphery of existing web pages a small tab that, when clicked by visitors, expands into a panel containing questions commonly asked about the host web page. By clicking on one of the common questions, a visitor receives the corresponding answer. The panel then shrinks back into a tab, allowing the visitor to continue with their web-based task, having received instant, self-service help with no typing and only a few clicks. AnswerDash emerged from co-founder Andrew Ko's National Science Foundation-funded research project conducted at the University of Washington. The research investigated web-scale analytics about questions that users have regarding website functionality and content. As part of the project he and his research partner deployed prototypes of what would form the basis for AnswerDash at the UW Libraries, UW School of Medicine and UW Information School. Seeing how the tool worked, they realized that providing instant answers to website visitors was not limited to an academic research setting; businesses could benefit by making the information their customers need available quickly and easily. Upon making that realization, forming a company to commercialize their work was an obvious choice. Technology & Web The work at the University of Washington was supported by research funding from the National Science Foundation.

Aortica Corporation aortica-corporation 2017 0 UniversityofWashington 2014 WA 1 Aortica Corp. has developed proprietary software that enables vascular surgeons to treat patients with complex abdominal aortic aneurysms (AAA) using less invasive endograft therapy rather than highly invasive open surgery. An aortic aneurysm is a bulge that develops in the largest artery in the human body. If untreated it could burst causing massive bleeding and most often – death. Placement of endografts (tubular stents that channel blood flow away from the aneurysm) have become the preferred method of treatment. Unfortunately, many patients have branch arteries surrounding the aneurysm that do not allow for proper anchoring of an endograft. Aortica Corp.’s AortaFit™ software allows physicians and graft manufacturers to navigate these branch arteries and safely place the endograft. Aortica Corp. has developed proprietary software that enables vascular surgeons to treat patients with complex abdominal aortic aneurysms (AAA) using less invasive endograft therapy rather than highly invasive open surgery. An aortic aneurysm is a bulge that develops in the largest artery in the human body. If untreated it could burst causing massive bleeding and most often – death. Placement of endografts (tubular stents that channel blood flow away from the aneurysm) have become the preferred method of treatment. Unfortunately, many patients have branch arteries surrounding the aneurysm that do not allow for proper anchoring of an endograft. Aortica Corp.’s AortaFit™ software allows physicians and graft manufacturers to navigate these branch arteries and safely place the endograft. The AortaFit is the result of company founder and vascular surgeon Benjamin Starnes seeing a need and finding the solution. As chief of vascular surgery at the University of Washington (UW), specializing in the treatment of aortic disease, he was often frustrated with the lack of treatment options for patients with complex AAA disease. Dr. Starnes began to manually modify standard endografts to account for the branch arteries around aneurysms. The process is called “fenestrated endovascular aneurysm repair” (FEVAR) and involves creating a hole in a standard endograft, which allows blood to continue to perfuse branch arteries and feed vital organs. His methodology was extremely effective and saved patients the trauma of open surgery, but it was very time consuming, expensive and required high level of expertise to perform. Consequently, it was not easily transferable to other physicians. Dr. Starnes began working with UW researchers to automate the process. This resulted in software, that when combined with a patient’s CT scan and 3D printing, produced a template to guide physician modification of a standard endograft. Aortica was founded to further develop and commercialize this technology Technology & Web Funding from the National Institutes of Health helped support the foundational work conducted at UW that led to the formation of Aortica Corp.

Applied Dexterity, Inc. applied-dexterity-inc 2017 0 UniversityofWashington 2012 WA 1 Applied Dexterity produces and sells the RAVEN surgical robotics research platform. Research institutions can use this system as a test-bed for new developments in surgical robotics. RAVEN is designed to be an extensible, robust, and programmable research tool to allow researchers in engineering, surgery, and computer science to experiment, innovate, and collaborate. Applied Dexterity produces and sells the RAVEN surgical robotics research platform. Research institutions can use this system as a test-bed for new developments in surgical robotics. RAVEN is designed to be an extensible, robust, and programmable research tool to allow researchers in engineering, surgery, and computer science to experiment, innovate, and collaborate. RAVEN was originally developed from 2002-2007 at the University of Washington with funding from the Department of Defense. The army wanted a small robust surgical robot that could be deployed on the battlefield and tele-operated by remote surgeons, out of harm’s way. UW faculty Blake Hannaford and Jacob Rosen led the team that researched, designed and developed the RAVEN. In 2010, the National Science Foundation funded an update of the RAVEN design resulting in RAVEN-II. In late 2012, Applied Dexterity was founded to sell and provide ongoing support for the RAVEN systems, which are now installed in 18 laboratories worldwide. Technology & Web The work conducted at the University of Washington was supported by research funding from the Department of Defense and the National Science Foundation.

AptaMatrix aptamatrix 2013 0 SyracuseUniversity 2003 NY 1 AptaMatrix’s focus is to accelerate the rate of aptamer discovery using its patent pending Acyclic Identification of Aptamers (AIA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of creating rapid diagnostic tools for detection of chemical and biological targets, and leveraging this diagnostic platform for drug discovery applications.Aptamers are DNA/RNA molecules that have affinities for their targets similar to antibodies. Aptamers have shown great potential to replace antibodies in biosensors, point-of-care diagnostics, therapeutics, and all of the areas currently dominated by antibodies. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. AptaMatrix’s focus is to accelerate the rate of aptamer discovery using its patent pending Acyclic Identification of Aptamers (AIA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of creating rapid diagnostic tools for detection of chemical and biological targets, and leveraging this diagnostic platform for drug discovery applications.Aptamers are DNA/RNA molecules that have affinities for their targets similar to antibodies. Aptamers have shown great potential to replace antibodies in biosensors, point-of-care diagnostics, therapeutics, and all of the areas currently dominated by antibodies. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. Syracuse University chemistry professor Philip Borer’s ground-breaking research is at the core of both the AIA method and the AlloSwitch technology. Borer’s research specializes in the structure and stability of nucleic acids and their complexes with proteins.The AlloSwitch concept was developed at Syracuse in collaboration with fellow chemistry professor Bruce Hudson as an ultrasensitive method to detect binding to the nucleocapsid protein from HIV-1. Hudson and Borer had collaborated for many years in anti-AIDS research, however it became clear that AlloSwitch technology had wide application in contaminant sensing and drug discovery. Defense, Safety, & Aerospace The fundamental research behind AptaMatrix was conducted at Syracuse University with funding from the National Institutes of Health.

Arbor Networks arbor-networks 2010 0 UniversityofMichigan 2000 MA 101 Arbor Networks is an online security company launched in 2000 by University of Michigan Computer Science professor Dr. Farnam Jahanian and doctoral student G. Robert Malan, who had developed technology in the University of Michigan Software Systems Lab. The company boasts a 70 percent market share and 300 customers around the world. Their security solutions, which manage and protect the entire network — from the network core to the broadband edge — are deployed in the backbones of all the major service provider and MSO networks across the globe, including MCI, Sprint, AT&T, Earthlink, Asia Netcom and British Telecom. In 2006, Arbor Networks was named one of the twenty fastest growing private companies in North America. In August 2010, Arbor Networks was acquired by Tektronix Communications of Plano, TX. Recent News Arbor Networks founder Farnam Jahanian to head NSF Computer & Information Science & Engineering Directorate. Learn more Arbor Networks is an online security company launched in 2000 by University of Michigan Computer Science professor Dr. Farnam Jahanian and doctoral student G. Robert Malan, who had developed technology in the University of Michigan Software Systems Lab. The company boasts a 70 percent market share and 300 customers around the world. Their security solutions, which manage and protect the entire network — from the network core to the broadband edge — are deployed in the backbones of all the major service provider and MSO networks across the globe, including MCI, Sprint, AT&T, Earthlink, Asia Netcom and British Telecom. In 2006, Arbor Networks was named one of the twenty fastest growing private companies in North America. In August 2010, Arbor Networks was acquired by Tektronix Communications of Plano, TX. Recent News Arbor Networks founder Farnam Jahanian to head NSF Computer & Information Science & Engineering Directorate. Learn more The company was launched in 2000 by University of Michigan computer science professor Dr. Farnam Jahanian and doctoral student G. Robert Malan, who had developed the technology in the U-M Software Systems Lab. Dr. Jahanian serves as Chairman of the Board and Dr. Malan as Chief Technology Officer. Arbor Networks maintains R&D facilities in Ann Arbor, Michigan and has added over 60 jobs and an estimated $20 million to the local economy Technology & Web FARNAM JAHANIAN The network security research conducted at the University of Michigan Software Systems Lab was supported by a $1.5 million grant from the Department of Defense, through the Defense Advanced Research Projects Agency (DARPA). Earlier networking research was supported by grants from the National Science Foundation.

ArmaGen Technologies, Inc. armagen-technologies-inc 2010 0 UniversityofCaliforniaLosAngelesUniversityofCalifornia 2004 CA 1 In the 1980s, Dr. William Pardridge, Professor of Medicine and Endocrinology at the University of California, Los Angeles (UCLA), and his research team were the first to show that there were receptor systems along the human blood-brain barrier (BBB) that acted as transport systems. In the two decades since, they have continued their research and, with the help of funding from the National Institutes of Health and the Department of Defense, have developed what they call “molecular Trojan horses” that can effectively deliver various drugs and gene therapies to the brain. ArmaGen Technologies, Inc. was founded in 2004 to use this technology to develop therapeutic products for treatment of conditions including Alzheimer’s disease, Parkinson’s disease, stroke, and brain cancer. In the 1980s, Dr. William Pardridge, Professor of Medicine and Endocrinology at the University of California, Los Angeles (UCLA), and his research team were the first to show that there were receptor systems along the human blood-brain barrier (BBB) that acted as transport systems. In the two decades since, they have continued their research and, with the help of funding from the National Institutes of Health and the Department of Defense, have developed what they call “molecular Trojan horses” that can effectively deliver various drugs and gene therapies to the brain. ArmaGen Technologies, Inc. was founded in 2004 to use this technology to develop therapeutic products for treatment of conditions including Alzheimer’s disease, Parkinson’s disease, stroke, and brain cancer. ArmaGen Technologies, Inc. was founded in 2004 by Dr. William Pardridge, Professor of Medicine and Endocrinology at UCLA. The company is a spin-off from Dr. Pardridge’s laboratory at UCLA. When it was founded in 2004, ArmaGen signed a patent agreement with the University of California that gave the company exclusive license rights to pending and world-wide issued patents comprising a broad patent estate covering multiple technology platforms for the delivery to the brain, and other organs, of drugs, recombinant proteins, and non-viral gene medicines. Biomedical Dr. Pardridge’s research at UCLA has been funded by the National Institutes of Health and the Department of Defense. ArmaGen has received recent awards from the National Institute of Neurological Disorders and Stroke (NINDS) at NIH (September 2008) and the US Army (June 2008).

Arvinas arvinas 2017 0 YaleUniversity 2013 CT 1 Arvinas is developing a new class of drugs that employs the body’s own internal systems to eliminate the “rogue,” or uncontrolled, proteins that lead to disease, creating new and better therapies for hematological cancers. Using a novel platform technology, PROTAC™, Arvinas creates small molecule drugs that bind to disease-causing proteins and “tags” them for degradation by the ubiquitin/proteasome system – part of the natural process for the turnover of proteins in the cell. In so doing, the targeted proteins are eliminated and the cancer cell is no longer able to grow. In contrast, traditional drugs function as inhibitors, temporarily binding to and blocking the function of certain proteins. But this approach requires very high, and often toxic, dosing levels and only works on 25 percent of the body’s proteins. Arvinas is developing a new class of drugs that employs the body’s own internal systems to eliminate the “rogue,” or uncontrolled, proteins that lead to disease, creating new and better therapies for hematological cancers. Using a novel platform technology, PROTAC™, Arvinas creates small molecule drugs that bind to disease-causing proteins and “tags” them for degradation by the ubiquitin/proteasome system – part of the natural process for the turnover of proteins in the cell. In so doing, the targeted proteins are eliminated and the cancer cell is no longer able to grow. In contrast, traditional drugs function as inhibitors, temporarily binding to and blocking the function of certain proteins. But this approach requires very high, and often toxic, dosing levels and only works on 25 percent of the body’s proteins. Building on groundbreaking research at Yale University by Craig Crews, Ph.D., Arvinas’ Founder and Chief Scientific Advisor, Arvinas has developed a broad technology platform focused on high value targets, with the potential to deliver safer, more potent treatment than small molecule inhibitors, and to address the 75 percent of targets that evade inhibition and are currently undruggable. Crews’ basic research, which sought to develop a deeper understanding of the human cell, was conducted over decades and supported with grant funding from the National Institutes of Health. Biomedical The work conducted at Yale University was supported by research funding from the National Institutes of Health.

AsclepiX Therapeutics LLC asclepix-therapeutics-llc 2017 0 JohnsHopkinsUniversity 2011 MD 1 AsclepiX Therapeutics is creating breakthrough next gen therapies for angiogenesis and lymphangiogenesis diseases. The company addresses this critical issue across multiple diseases with therapies for ocular diseases, cancer, and tissue and organ transplant. They use bioinformatics methods to design and develop new peptide drugs and the latest in biomaterials and drug delivery to design long-lasting biodegradable nano- and microparticles to deliver their therapeutic peptides to different locations in the body. The first target for their novel drug delivery strategy is vision loss, specifically diabetic macular edema (DME). They are additionally developing drugs for other indications including Neovascular (wet) Age-Related Macular Degeneration (NVAMD), liver cancer, triple negative breast cancer, small cell lung cancer, brain cancer, and skin, limb, and organ transplant. AsclepiX Therapeutics is creating breakthrough next gen therapies for angiogenesis and lymphangiogenesis diseases. The company addresses this critical issue across multiple diseases with therapies for ocular diseases, cancer, and tissue and organ transplant. They use bioinformatics methods to design and develop new peptide drugs and the latest in biomaterials and drug delivery to design long-lasting biodegradable nano- and microparticles to deliver their therapeutic peptides to different locations in the body. The first target for their novel drug delivery strategy is vision loss, specifically diabetic macular edema (DME). They are additionally developing drugs for other indications including Neovascular (wet) Age-Related Macular Degeneration (NVAMD), liver cancer, triple negative breast cancer, small cell lung cancer, brain cancer, and skin, limb, and organ transplant. The company spun out from the Johns Hopkins University Department of Biomedical Engineering and Ophthalmology where JHU scientists Jordan Green and Aleksander Popel made their initial discoveries in cells and animal models. “When we looked at the eyes of mice that were a model of wet age-related macular degeneration and found that our peptide did not simply block aberrant blood vessel growth in the back of the eye, but reversed it and caused significant regression of the neovasculature, we knew that we discovered something special that could potentially reverse blindness in patients,” Green said. Their desire to see their work move from the lab to helping patients, led them to create AsclepiX to further develop and commercialize their technology. Biomedical Drs. Green and Popel’s work at Johns Hopkins was supported by the National Institutes of Health through the National Eye Institute, National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering.

Athenex athenex 2010 0 UniversityatBuffalo 2003 NY 1 Kinex Pharmaceuticals, now called Athenex, is developing next generation anti-cancer drugs that target the molecular basis of disease. The company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins. Mimetica™ is Kinex Pharmaceuticals’ patented technology for generating small molecule inhibitors of kinases and phosphatases that bind in the substrate pocket. The key advantage of the new protein kinase inhibitors that Kinex is developing is that because of the unique binding site against which these compounds are targeted, there is a greatly reduced chance that patients will develop resistance to these drugs — a problem that already has rendered ineffective some of the first marketed protein kinase inhibitors. Kinex Pharmaceuticals, now called Athenex, is developing next generation anti-cancer drugs that target the molecular basis of disease. The company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins. Mimetica™ is Kinex Pharmaceuticals’ patented technology for generating small molecule inhibitors of kinases and phosphatases that bind in the substrate pocket. The key advantage of the new protein kinase inhibitors that Kinex is developing is that because of the unique binding site against which these compounds are targeted, there is a greatly reduced chance that patients will develop resistance to these drugs — a problem that already has rendered ineffective some of the first marketed protein kinase inhibitors. Kinex was formed in 2003 based on the basic research of David Hangauer, PhD, associate professor of medicinal chemistry in the Department of Chemistry in University at Buffalo’s College of Arts and Sciences. Kinex is commercializing Hangauer’s unique method for designing and synthesizing anti-cancer compounds. Phase I clinical testing of Kinex’s lead compound, KX-01, has been completed. A second compound is in pre-clinical testing. Biomedical The original research conducted at University at Buffalo was supported with funding from the National Institutes of Health.

Audyssey Laboratories audyssey-laboratories 2010 0 UniversityofSouthernCalifornia 2002 CA NA Audyssey Laboratories is an audio sound technology company that has created a high-tech sound system that produces accurate, enveloping and distortion-free sound everywhere in one’s listening room. Audyssey Laboratories has developed world class sound technologies for home, business and automotive use. In late 1996, the National Science Foundation established a unique research center at University of Southern California (USC) that focused on immersive technologies. A key component of the Integrated Media Systems Center (IMSC) is the Immersive Audio Laboratory that was founded by Chris Kyriakakis and Tomlinson Holman. Over the past 10 years Tom and Chris have conducted research in audio signal processing, acoustics, and psychoacoustics. The results of their interdisciplinary research have been published in more than 100 technical journals and several books. One of the most challenging problems that they addressed was the comprehensive understanding of the negative effects of room acoustics on sound reproduction. It took five years of intense research and experimentation and more than $6 million in research funds to fully understand and solve this intricate problem. No other facility in the world had the scientific expertise and the resources to fundamentally examine and solve this problem. UPDATE: 12/20/10 The company, which has designed high-end home theater systems since 2002, just introduced an iPod dock that follows a vertical, rather than horizontal, format. Learn more about their innovation here. UPDATE: 9/6/2011 Audyssey founder and University of Southern California engineer Chris Kyriakakis explains the technology behind “pyschoacoustics,” the study of sound perception by the human auditory system, in the New York Times: “Sound, the Way the Brain Prefers to Hear It.” Audyssey Laboratories is an audio sound technology company that has created a high-tech sound system that produces accurate, enveloping and distortion-free sound everywhere in one’s listening room. Audyssey Laboratories has developed world class sound technologies for home, business and automotive use. In late 1996, the National Science Foundation established a unique research center at University of Southern California (USC) that focused on immersive technologies. A key component of the Integrated Media Systems Center (IMSC) is the Immersive Audio Laboratory that was founded by Chris Kyriakakis and Tomlinson Holman. Over the past 10 years Tom and Chris have conducted research in audio signal processing, acoustics, and psychoacoustics. The results of their interdisciplinary research have been published in more than 100 technical journals and several books. One of the most challenging problems that they addressed was the comprehensive understanding of the negative effects of room acoustics on sound reproduction. It took five years of intense research and experimentation and more than $6 million in research funds to fully understand and solve this intricate problem. No other facility in the world had the scientific expertise and the resources to fundamentally examine and solve this problem. UPDATE: 12/20/10 The company, which has designed high-end home theater systems since 2002, just introduced an iPod dock that follows a vertical, rather than horizontal, format. Learn more about their innovation here. UPDATE: 9/6/2011 Audyssey founder and University of Southern California engineer Chris Kyriakakis explains the technology behind “pyschoacoustics,” the study of sound perception by the human auditory system, in the New York Times: “Sound, the Way the Brain Prefers to Hear It.” Audyssey Laboratories was conceived at the prestigious Immersive Audio Laboratory at the University of Southern California in Los Angeles, California. Dr. Sunil Bharitkar, Philip Hilmes, Prof. Tomlinson Holman, and Prof. Chris Kyriakakis were all involved in conceiving and creating the technology that was the basis for “spinning out” the company in July, 2002. Today, they are, respectively, Audyssey’s Vice President for Research, Vice President for Engineering, Chief Scientist, and Chief Technology Officer. Technology & Web The National Science Foundation established the research center at USC that focused on immersive technologies, where Audyssey was conceived.

Aurrion aurrion 2013 0 UniversityofCaliforniaSantaBarbaraUniversityofCalifornia 2007 CA 1 Aurrion is a privately held company located in Santa Barbara, CA. The hybrid silicon photon integration platform the company is commercializing will enable a new generation of integrated photonic devices.Aurrion is partnering with system integrators to create new systems on chips that can provide a massive ( >10x) reduction in size and weight over discretely implemented designs while providing improved power, cost, and reliability by eliminating unnecessary packaging and optical connections. In November 2011, Aurrion was awarded a $13.9M R&D contract from the U.S. Department of Defense. Aurrion is a privately held company located in Santa Barbara, CA. The hybrid silicon photon integration platform the company is commercializing will enable a new generation of integrated photonic devices.Aurrion is partnering with system integrators to create new systems on chips that can provide a massive ( >10x) reduction in size and weight over discretely implemented designs while providing improved power, cost, and reliability by eliminating unnecessary packaging and optical connections. In November 2011, Aurrion was awarded a $13.9M R&D contract from the U.S. Department of Defense. The fundamental technology for Aurrion’s silicon photon integration platform was originally developed at the University of California, Santa Barbara, where company founder John Bowers is a professor of electrical and computer engineering and of materials and co-founder Alexander Fang received his M.S. and Ph.D. in electrical engineering. While at UCSB, Dr. Fang developed the hybrid silicon laser platform, demonstrating the first electrically pumped lasers on silicon. Materials Alexander W. Fang The work at UCSB that led to the development of Aurrion’s technology was supported by approximately $5 million in grants from the Army Research Office.

Aursos, Inc. aursos-inc 2010 0 MichiganTechnologicalUniversity 2007 MI NA Why is it that, while humans begin to show reduced bone mass and strength after even short periods of inactivity, black bears can hibernate for up to seven months and emerge without any loss in bone mass or strength? Dr. Seth Donahue and researchers at Michigan Technological University thought it was a question worth asking. The result was the isolation of a “bone-building biomarker” in the blood of black bears, which has great promise for osteoperosis treatment and prevention. Aursos was founded in March of 2007. The company has licensed Dr. Donahue’s technology with an eye toward commercializing the therapeutic compounds found in black bears for the treatment and prevention of osteoporosis. Why is it that, while humans begin to show reduced bone mass and strength after even short periods of inactivity, black bears can hibernate for up to seven months and emerge without any loss in bone mass or strength? Dr. Seth Donahue and researchers at Michigan Technological University thought it was a question worth asking. The result was the isolation of a “bone-building biomarker” in the blood of black bears, which has great promise for osteoperosis treatment and prevention. Aursos was founded in March of 2007. The company has licensed Dr. Donahue’s technology with an eye toward commercializing the therapeutic compounds found in black bears for the treatment and prevention of osteoporosis. Aursos is based upon patent-pending research discoveries from the laboratory of Dr. Seth Donahue at Michigan Technological University. The company has continued to sponsor research and validation of the technology in Dr. Donahue’s lab. Biomedical The research validating Dr. Donahue’s discoveries was sponsored by the Michigan Universities Commercialization Initiative and the National Institutes of Health. Aursos, with partner Proteos, Inc. in Kalamazoo, Michigan, has received critical National Institutes of Health Small Business Technology Transfer funding for follow-on laboratory validation work conducted at Michigan Technological University.

Autonomic Materials, Inc. autonomic-materials-inc 2013 0 UniversityofIllinoisatUrbana-Champaign 2005 IL 1 Autonomic Materials (AMI)is focused on developing and commercializing breakthrough low-cost, self-healing polymer systems for high performance coatings and structural composites. This platform technology can be readily incorporated into existing coatings of virtually all types, greatly extending useful lifetimes in a number of industrial applications.AMI's innovations translate to increased value for coatings producers and users alike. Recoating intervals are lengthened, minimizing labor costs and equipment downtime. Additionally, by extending coating lifetimes, environmental impact is minimized. Autonomic Materials (AMI)is focused on developing and commercializing breakthrough low-cost, self-healing polymer systems for high performance coatings and structural composites. This platform technology can be readily incorporated into existing coatings of virtually all types, greatly extending useful lifetimes in a number of industrial applications.AMI's innovations translate to increased value for coatings producers and users alike. Recoating intervals are lengthened, minimizing labor costs and equipment downtime. Additionally, by extending coating lifetimes, environmental impact is minimized. Dr. Scott White, professor of aerospace engineering at the University of Illinois, founded Autonomic Materials in 2005. Dr. White is also the leader of the Autonomous Materials Systems (AMS) group at University of Illinois’ world-renowned Beckman Institute. This multidisciplinary research team has been developing breakthrough technologies in the area of self-healing materials for a decade. It is the AMS group’s innovative technology platform that Autonomic Materials is currently bringing to the global coatings market to enable the production of SMART coatings. UI Professors Nancy Sottos, Jeff Moore, and Paul Braun were also involved in the research that led to the formation of Autonomic Materials. Materials The research that led to the founding of AMI was funded by the Air Force Office of Scientific Research and the National Science Foundation.

Auxadyne, LLC auxadyne-llc 2017 0 FloridaStateUniversity 2015 FL 1 Auxadyne’s foam technology does the unusual, it expands outward when stretched, meaning it gets thicker rather than thinner and making it ideal for protective equipment, medical devices and other applications. Indeed, the foam is so novel that within a few weeks of news announcing its intent to commercialize the technology, Auxadyne was contacted by top sporting equipment companies and companies making medical devices and ballistic vests. Auxadyne’s foam technology does the unusual, it expands outward when stretched, meaning it gets thicker rather than thinner and making it ideal for protective equipment, medical devices and other applications. Indeed, the foam is so novel that within a few weeks of news announcing its intent to commercialize the technology, Auxadyne was contacted by top sporting equipment companies and companies making medical devices and ballistic vests. Xylafoam, as the foam is called, is the outgrowth of 20 years of research at Florida State University and most directly an initiative sponsored by the U.S. Department of Veterans Affairs to develop a product that could aid amputees with prosthetic limbs. As inventor and company founder Changchun “Chad” Zeng with FSU’s High Performance Materials Institute explains, “For example, the socks that amputees currently use to attach prosthetic devices do not adjust to limb shape and volume, creating lots of problems. My invention solves those issues.” By the company’s one-year anniversary in 2016, it was negotiating a multi-year development contract with a major sports company and working on prototypes with medical device and first responder gear manufacturers. “As a direct result of this VA research funding, Auxadyne will create high-tech, high-wage manufacturing jobs in Florida allowing us to make the lives of leg amputees, military personnel, first responders and athletes of all ages safer,” said Zeng. Biomedical The work at Florida State University was supported by research funding from the Department of Defense and the U.S. Department of Veterans Affairs.

Avid Radiopharmaceuticals, Inc. avid-radiopharmaceuticals-inc 2010 0 UniversityofPennsylvania 2005 PA 1 Avid is a clinical-stage, product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Chronic diseases such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and diabetes with mellitus affect tens of millions of people worldwide. Avid is working to develop novel molecular imaging agents that allow the detection of the earliest stages of these diseases, before clinical symptoms develop. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer’s disease. Avid has demonstrated proof of mechanism in human trials with these agents. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson’s disease (PD), and has a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease. In 2010, Avid became a wholly owned subsidiary of Eli Lilly and Company, the 10th largest pharmaceutical company in the world. Avid is a clinical-stage, product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Chronic diseases such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and diabetes with mellitus affect tens of millions of people worldwide. Avid is working to develop novel molecular imaging agents that allow the detection of the earliest stages of these diseases, before clinical symptoms develop. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer’s disease. Avid has demonstrated proof of mechanism in human trials with these agents. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson’s disease (PD), and has a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease. In 2010, Avid became a wholly owned subsidiary of Eli Lilly and Company, the 10th largest pharmaceutical company in the world. The molecular imaging agents at the core of Avid’s work were originally developed by Dr. Hank Kung at the University of Pennsylvania. Dr. Kung, Professor of Radiology and Pharmacology at the University of Pennsylvania, serves as Avid’s Chief Scientific Advisor, Chairman of the Scientific Advisory Board. He is regarded as a world leader in research and development of innovative radiopharmaceuticals for diagnosis of brain diseases including Alzheimer’s disease and Parkinson’s disease. Avid founder Dr. Daniel Skovronsky was previously Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. He has more than 20 peer-reviewed publications and several National Institutes of Health funded grants on Alzheimer’s disease research. Biomedical The basic research at the University of Pennsylvania that led to the development of this technology was supported by research grants from the National Institutes of Health.

Axogen axogen 2013 0 UniversityofFlorida 2002 FL 1 AxoGen is a regenerative medicine company focused on the science, development and commercialization of technologies for peripheral nerve regeneration and reconstruction to help patients suffering from traumatic injuries or undergoing surgeries that impact the function of their peripheral nerves.Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. Axogen’s Avance® Nerve Graft for bridging the gap created when the nerve is severed has been used on more than 7,000 patients, including soldiers injured in Iraq and Afghanistan. AxoGen is a regenerative medicine company focused on the science, development and commercialization of technologies for peripheral nerve regeneration and reconstruction to help patients suffering from traumatic injuries or undergoing surgeries that impact the function of their peripheral nerves.Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. Axogen’s Avance® Nerve Graft for bridging the gap created when the nerve is severed has been used on more than 7,000 patients, including soldiers injured in Iraq and Afghanistan. Axogen is the result of University of Florida neuroscientist David Muir’s years of research on peripheral nerve damage. Historically, peripheral nerve repairs have been done with one of the patient’s own nerves, but this requires a second surgery and can cause its own lasting damage. Muir and his colleagues developed a technique for harvesting and treating nerve tissue from cadavers to remove cells and other tissue, leaving sterile hollow nerve channels through which the patient's own nerve can regenerate. Biomedical The initial research and development was undertaken at the University of Florida with a $1.5 million grant from the National Institutes of Health.

Axonia Medical, Inc. axonia-medical-inc 2013 0 UniversityofPennsylvania 2009 MI 1 Axonia Medical is pioneering a revolutionary approach to repair and restore damaged peripheral or central nervous systems using tissue-engineered nerve grafts (TENGs). By recapitulating the anatomy of the nervous system, TENGs act as living bridges for targeted repair of the nervous system, orchestrating a rapid, robust and complete regenerative response that promises improved restoration of sensory, motor and/or cognitive deficits. Axonia Medical’s first focus is the development of TENGs for repair of peripheral nerve injury (PNI) with follow on products for spinal cord injury (SCI), traumatic brain injury (TBI) and stroke. In addition, Axonia Medical will pursue opportunities for use of TENGs as a direct neural interface for programmable machines and computers (e.g., advanced prosthetic limbs). Axonia Medical is pioneering a revolutionary approach to repair and restore damaged peripheral or central nervous systems using tissue-engineered nerve grafts (TENGs). By recapitulating the anatomy of the nervous system, TENGs act as living bridges for targeted repair of the nervous system, orchestrating a rapid, robust and complete regenerative response that promises improved restoration of sensory, motor and/or cognitive deficits. Axonia Medical’s first focus is the development of TENGs for repair of peripheral nerve injury (PNI) with follow on products for spinal cord injury (SCI), traumatic brain injury (TBI) and stroke. In addition, Axonia Medical will pursue opportunities for use of TENGs as a direct neural interface for programmable machines and computers (e.g., advanced prosthetic limbs). Axonia Medical leverages the ground-breaking discoveries by Dr. Douglas Smith at the University of Pennsylvania regarding the growth of nerve axons to produce 3-dimenstional tissue-engineered nerve grafts that can repair and restore damaged regions of the nervous system. Dr. Smith is director of the Center for Brain Injury and Repair and professor of neurosurgery at U Penn's Perelman School of Medicine. Axonia Medical was formed by Dr. Smith and the University of Pennsylvania through its UPstart Company Incubator. Axonia Medical holds an exclusive worldwide license to the relevant intellectual property owned by the University of Pennsylvania. Biomedical The research that led to the technologies behind Axonia was supported with grants from the Department of Defense and the National Institutes of Health. The company is led by CEO Harry Ledebur, a molecular and cell biologist by training.

AzERx, Inc. azerx-inc 2010 0 ArizonaStateUniversity 2004 AZ 1 Arizona